<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446885</url>
  </required_header>
  <id_info>
    <org_study_id>IIR-USA-001277</org_study_id>
    <nct_id>NCT03446885</nct_id>
  </id_info>
  <brief_title>Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD</brief_title>
  <official_title>Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With Attention-deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregory Fabiano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There has been little research on the third area of impairment noted in the Diagnostic and&#xD;
      Statistical Manual of Mental Disorders - &quot;occupational functioning.&quot; Individuals with ADHD&#xD;
      experience job-related impairments including a greater likelihood of being unemployed and not&#xD;
      enrolled in school and for those that were employed they were in a lower status occupation,&#xD;
      relative to typically-developing comparison peers. The current literature on analogue&#xD;
      workplace settings and the effects of lisdexamfetamine dimesylate includes office-based tasks&#xD;
      similar to school seat work. Unfortunately, this is inconsistent with the typical work&#xD;
      environment most common for individuals with disabilities such as ADHD where food preparation&#xD;
      is the most common job following high school. Therefore, medication effects in this type of&#xD;
      setting, most common for individuals with ADHD entering the workforce, need to be studied.&#xD;
      The investigators propose to study workplace behavior in an analogue work setting in a&#xD;
      laboratory &quot;pizza place.&quot; Individuals with ADHD will participate in an interview with a&#xD;
      supervisor each day, have a list of deliveries that need to be managed, deal with situations&#xD;
      that require occupational judgment and appropriate customer service, and drive to make&#xD;
      deliveries accurately and on-time. These behaviors can be reliably assessed within the&#xD;
      laboratory. Twenty young adults will participate in two &quot;workdays&quot; within a randomized,&#xD;
      double-blind, placebo-controlled design wherein participants will be administered placebo and&#xD;
      .3 mg/kg lisdexamfetamine dimesylate in a counter-balanced order.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">February 11, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All participants received placebo and 40 mg Vyvanse in a cross-over design. Order of administration was randomly assigned and counter-balanced across participants</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratings of Job Application Quality</measure>
    <time_frame>during interventional study session, 1 day in duration</time_frame>
    <description>Three independent coders will review each de-identified application. Following the review of the application, coders will complete a rating form that asks them to make an overall evaluation regarding whether the person was an acceptable job candidate for an interview using a scale of 1 (&quot;definitely not&quot;) to 5 (&quot;definitely&quot;). Average rating across coders will be used as the dependent measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratings of Job Interview Performance</measure>
    <time_frame>during interventional study session, 1 day in duration</time_frame>
    <description>Three coders who are unaware of the study participant identities or group status will view the job interview videotape and completed a form. Raters will provide a rating of their overall impression of the interview behavior ranging from a score of one (Poor) to four (Outstanding). The average score of the coders will be utilized as a dependent measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Observation of Workplace Productivity</measure>
    <time_frame>during interventional study session, 1 day in duration</time_frame>
    <description>The dependent measures from this aspect of the study are the number of items completed correctly out of the total number of assigned items (i.e., 225). Thus, the score reflects the percentage of items correctly completed out of the 225 assigned and scores could range from 0-100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inattentive/Overactive Rating</measure>
    <time_frame>during interventional study session, 1 day in duration</time_frame>
    <description>In addition to ratings of the interview performance, the rater also will complete the five-item inattentive/overactive (I/O) factor of the Iowa Conners rating scale (Atkins, Pelham, &amp; Licht, 1989; Loney &amp; Milich, 1982; Pelham, Milich, Murphy, &amp; Murphy, 1989). The five items are rated on a scale of Not at all (0) to Very Much (3) and the sum of these items represents the score. The dependent measure will be the score averaged across raters. Scores can range from 0-3 on each item, and the average score of the 5 items was used. Higher scores reflect greater inattentive/overactivity-related behaviors.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Lab visit 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lab visit 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine Dimesylate 40 MG</intervention_name>
    <description>Lisdexamfetamine Dimesylate 40 MG administered orally</description>
    <arm_group_label>Lab visit 1</arm_group_label>
    <arm_group_label>Lab visit 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule administered orally</description>
    <arm_group_label>Lab visit 1</arm_group_label>
    <arm_group_label>Lab visit 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of ADHD&#xD;
&#xD;
          -  parental permission and/or teen consent/assent as appropriate&#xD;
&#xD;
          -  between 16-25 years of age&#xD;
&#xD;
          -  IQ greater than or equal to 70&#xD;
&#xD;
          -  permit or license to drive&#xD;
&#xD;
          -  ability to read and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any medical condition that would contraindicate use of stimulant medication&#xD;
&#xD;
          -  any prior adverse response to lisdexamfetamine dimesylate or other stimulant&#xD;
             medication&#xD;
&#xD;
          -  use of concurrent,non-stimulant psychoactive medication&#xD;
&#xD;
          -  diagnosis of schizophrenia or presence of thought disorder symptoms&#xD;
&#xD;
          -  autism spectrum disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SUNY at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <results_first_submitted>September 23, 2020</results_first_submitted>
  <results_first_submitted_qc>June 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2021</results_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Gregory Fabiano</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03446885/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allocated to Vyvanse First</title>
          <description>Administration of Vyvanse 40 mg then placebo on different days in a cross-over design</description>
        </group>
        <group group_id="P2">
          <title>Allocated to Placebo First</title>
          <description>Allocated to placebo then Vyvanse 40 mg on different days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not complete entire visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ADHD Participant</title>
          <description>Administration of placebo capsule/Vyvanse 40 mg on different days in a cross-over design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.76" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Currently prescribed stimulant medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratings of Job Application Quality</title>
        <description>Three independent coders will review each de-identified application. Following the review of the application, coders will complete a rating form that asks them to make an overall evaluation regarding whether the person was an acceptable job candidate for an interview using a scale of 1 (&quot;definitely not&quot;) to 5 (&quot;definitely&quot;). Average rating across coders will be used as the dependent measure.</description>
        <time_frame>during interventional study session, 1 day in duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Vyvanse</title>
            <description>40 mg Vyvanse</description>
          </group>
        </group_list>
        <measure>
          <title>Ratings of Job Application Quality</title>
          <description>Three independent coders will review each de-identified application. Following the review of the application, coders will complete a rating form that asks them to make an overall evaluation regarding whether the person was an acceptable job candidate for an interview using a scale of 1 (&quot;definitely not&quot;) to 5 (&quot;definitely&quot;). Average rating across coders will be used as the dependent measure.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="1.03"/>
                    <measurement group_id="O2" value="3.56" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratings of Job Interview Performance</title>
        <description>Three coders who are unaware of the study participant identities or group status will view the job interview videotape and completed a form. Raters will provide a rating of their overall impression of the interview behavior ranging from a score of one (Poor) to four (Outstanding). The average score of the coders will be utilized as a dependent measure.</description>
        <time_frame>during interventional study session, 1 day in duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.&#xD;
Lisdexamfetamine Dimesylate 40 MG: Lisdexamfetamine Dimesylate 40 MG administered orally&#xD;
Placebo: Placebo capsule administered orally</description>
          </group>
          <group group_id="O2">
            <title>Vyvanse</title>
            <description>40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.&#xD;
Lisdexamfetamine Dimesylate 40 MG: Lisdexamfetamine Dimesylate 40 MG administered orally&#xD;
Placebo: Placebo capsule administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Ratings of Job Interview Performance</title>
          <description>Three coders who are unaware of the study participant identities or group status will view the job interview videotape and completed a form. Raters will provide a rating of their overall impression of the interview behavior ranging from a score of one (Poor) to four (Outstanding). The average score of the coders will be utilized as a dependent measure.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread=".76"/>
                    <measurement group_id="O2" value="3.33" spread=".91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Observation of Workplace Productivity</title>
        <description>The dependent measures from this aspect of the study are the number of items completed correctly out of the total number of assigned items (i.e., 225). Thus, the score reflects the percentage of items correctly completed out of the 225 assigned and scores could range from 0-100.</description>
        <time_frame>during interventional study session, 1 day in duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.&#xD;
Lisdexamfetamine Dimesylate 40 MG: Lisdexamfetamine Dimesylate 40 MG administered orally&#xD;
Placebo: Placebo capsule administered orally</description>
          </group>
          <group group_id="O2">
            <title>Vyvanse</title>
            <description>40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.&#xD;
Lisdexamfetamine Dimesylate 40 MG: Lisdexamfetamine Dimesylate 40 MG administered orally&#xD;
Placebo: Placebo capsule administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Observation of Workplace Productivity</title>
          <description>The dependent measures from this aspect of the study are the number of items completed correctly out of the total number of assigned items (i.e., 225). Thus, the score reflects the percentage of items correctly completed out of the 225 assigned and scores could range from 0-100.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.60" spread="17.55"/>
                    <measurement group_id="O2" value="68.45" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inattentive/Overactive Rating</title>
        <description>In addition to ratings of the interview performance, the rater also will complete the five-item inattentive/overactive (I/O) factor of the Iowa Conners rating scale (Atkins, Pelham, &amp; Licht, 1989; Loney &amp; Milich, 1982; Pelham, Milich, Murphy, &amp; Murphy, 1989). The five items are rated on a scale of Not at all (0) to Very Much (3) and the sum of these items represents the score. The dependent measure will be the score averaged across raters. Scores can range from 0-3 on each item, and the average score of the 5 items was used. Higher scores reflect greater inattentive/overactivity-related behaviors.</description>
        <time_frame>during interventional study session, 1 day in duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.&#xD;
Lisdexamfetamine Dimesylate 40 MG: Lisdexamfetamine Dimesylate 40 MG administered orally&#xD;
Placebo: Placebo capsule administered orally</description>
          </group>
          <group group_id="O2">
            <title>Vyvanse</title>
            <description>40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.&#xD;
Lisdexamfetamine Dimesylate 40 MG: Lisdexamfetamine Dimesylate 40 MG administered orally&#xD;
Placebo: Placebo capsule administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Inattentive/Overactive Rating</title>
          <description>In addition to ratings of the interview performance, the rater also will complete the five-item inattentive/overactive (I/O) factor of the Iowa Conners rating scale (Atkins, Pelham, &amp; Licht, 1989; Loney &amp; Milich, 1982; Pelham, Milich, Murphy, &amp; Murphy, 1989). The five items are rated on a scale of Not at all (0) to Very Much (3) and the sum of these items represents the score. The dependent measure will be the score averaged across raters. Scores can range from 0-3 on each item, and the average score of the 5 items was used. Higher scores reflect greater inattentive/overactivity-related behaviors.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="1.33"/>
                    <measurement group_id="O2" value="2.01" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each condition in the study (i.e., placebo, Vyvanse) was administered on a single day, approximately one week apart, for each participant. Adverse events were evaluated for the day of administration of each condition.</time_frame>
      <desc>The definition was not different from clinicaltrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Vyvanse</title>
          <description>40 mg Vyvanse</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gregory A. Fabiano, Ph.D.</name_or_title>
      <organization>Florida International University</organization>
      <phone>716-359-7823</phone>
      <email>gfabiano@fiu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

